MFDS — authorised 18 December 2013
- Marketing authorisation holder: GLAXOSMITHKLINE
- Status: likely_approved
🇰🇷 Incruse Ellipta in South Korea
MFDS authorised Incruse Ellipta on 18 December 2013
Marketing authorisation
Incruse Ellipta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory approved in South Korea
Frequently asked questions
Is Incruse Ellipta approved in South Korea?
Yes. MFDS authorised it on 18 December 2013.
Who is the marketing authorisation holder for Incruse Ellipta in South Korea?
GLAXOSMITHKLINE holds the South Korean marketing authorisation.